Rocket Pharmaceuticals, Inc.
DE ˙ DB ˙ US77313F1066
2,44 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:9IP1 / Rocket Pharmaceuticals, Inc.
InstitutionE Fund Management Co., Ltd.
Latest Disclosed Ownership17,751 shares
Latest Disclosed Value $ 63,549
E Fund Management Co., Ltd. ownership in 9IP1 / Rocket Pharmaceuticals, Inc.

On April 13, 2026 - E Fund Management Co., Ltd. filed a 13F-HR form disclosing ownership of 17,751 shares of Rocket Pharmaceuticals, Inc. (DE:9IP1) valued at $49,969 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 15, 2025 disclosing 0 shares of Rocket Pharmaceuticals, Inc.. The current value of the position is $43,312 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-13 2026-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 17,751 17,751 64 0.0019
2025-08-15 2025-06-30 13F Rocket Pharmaceuticals Common Stock 77313F106 0 -14,567 -100.00 0 -100.00
2025-05-13 2025-03-31 13F Rocket Pharmaceuticals Common Stock 77313F106 14,567 3,513 31.78 97 -29.71 0.0046
2025-02-07 2024-12-31 13F Rocket Pharmaceuticals Common Stock 77313F106 11,054 11,054 139 0.0070
2024-08-12 2024-06-30 13F Rocket Pharmaceuticals Common Stock 77313F106 0 -15,549 -100.00 0 -100.00
2024-05-13 2024-03-31 13F Rocket Pharmaceuticals Common Stock 77313F106 15,549 4,352 38.87 419 24.78 0.0259
2024-02-07 2023-12-31 13F Rocket Pharmaceuticals Common Stock 77313F106 11,197 -1,215 -9.79 336 0.0213
2023-11-13 2023-09-30 13F Rocket Pharmaceuticals Common Stock 77313F106 12,412 -120 -0.96 0 0.0193
2023-08-11 2023-06-30 13F Rocket Pharmaceuticals Common Stock 77313F106 12,532 -4,469 -26.29 0 0.0197
2023-05-11 2023-03-31 13F Rocket Pharmaceuticals Common Stock 77313F106 17,001 1,601 10.40 0 -100.00 0.0212
2023-02-14 2022-12-31 13F Rocket Pharmaceuticals Common Stock 77313F106 15,400 -178 -1.14 301 20.88 0.0250
2022-11-14 2022-09-30 13F Rocket Pharmaceuticals Common Stock 77313F106 15,578 12,992 502.40 249 116.52 0.0232
2021-05-12 2021-03-31 13F ROCKET PHARMACEUTICALS Common Stock 77313F106 2,586 2,586 115 0.0092
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.